论文信息 - Case Report: Haemolytic anaemia with ceftazidime use in a patient with cystic fibrosis

Case Report: Haemolytic anaemia with ceftazidime use in a patient with cystic fibrosis

Drug-induced Immune Haemolytic Anaemia (DIIHA) is a rare but serious complication of cephalosporin use. Ceftazidime is recognized to be a rare cause of DIIHA. We report and discuss a case of DIIHA in a person with cystic fibrosis who developed severe haemolytic anaemia following use of ceftazidime in the management of an acute pseudomonal pulmonary exacerbation.

M. Walshaw | J. Yong | F. Frost | D. Nazareth

[1] Fei Chen,et al. Severe drug-induced immune haemolytic anaemia due to ceftazidime. , 2014, Blood transfusion = Trasfusione del sangue.

[2] G. Garratty,et al. Cross-reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other: cephalosporins and penicillin. , 2002, American journal of clinical pathology.

[3] C. Mueller-Eckhardt,et al. Drug‐induced immune hemolytic anemia , 1992, Transfusion.

[4] L. Chambers,et al. Ceftazidime-induced hemolysis in a patient with drug-dependent antibodies reactive by immune complex and drug adsorption mechanisms. , 1991, American journal of clinical pathology.